0001437749-26-017236
SEC filingOperating losses widened 53% to -$8.1M in Q1 FY2026 as grant revenue fell to zero from $1.9M prior year, driven by NIA funding exhaustion post-trial completion amid advancing neflamapimod development.
Net income followed suit, expanding 63% to -$8.0M from -$4.9M, yielding diluted EPS of -$0.86 versus -$0.56 year-over-year. Operating cash burn intensified to -$8.0M from -$3.9M, mirroring the P&L dynamics without grant inflows to provide relief. Management highlights that future capital needs hinge on variables like development timelines for neflamapimod, with operating plans potentially requiring additional funding.
Looking forward, the company anticipates escalating research and development expenses alongside general and administrative costs as headcount grows to bolster continued R&D activities. Capital expenditures are also expected to rise. Without successful capital raises, CervoMed may need to delay, reduce, or terminate development efforts for neflamapimod, emphasizing liquidity as a critical watch item for investors tracking this clinical-stage biopharma's path to value creation.